血管紧张肽转换酶抑制剂与血管紧张肽II受体拮抗剂的联合应用

Combinative application of angiotensin-converting enzyme inhibitors and angiotensin II antagonist

血管紧张肽转换酶抑制剂和血管紧张肽II受体拮抗剂是临床上已证实的非常有效的抗高血压药物 ,在近年来的研究中发现它们在降压的同时还具有显著的心、肾保护作用 ,并且已有一定数量的临床试验结果显示 ,将 2类药物联合应用可以获得更强大的靶器官保护作用 ,并不会增加不良反应。我们需要更多的大规模临床试验来进一步确证血管紧张肽转换酶抑制剂和血管紧张肽II受体拮抗剂联合用药在这方面的有效性和安全性 ,使心、肾功能不全及有蛋白尿的病人获得最有益的治疗。

Angiotensin-converting enzyme inhibitors and angiotensin II antagonist have been proven to be the effective and well tolerated antihypertensive agents.They also exhibit unique cardioprotective and renoprotective properties while they reduce the blood pressure.The results of a number of clinical trials support the notion that additive antihypertensive,cardioprotective and renoprotective effects may be obtained by combination of angiotensin-converting enzyme inhibitors with angiotensin- II antagonist in some patients.More studies are needed to confirm the effect and safety of the combination for the greatest benefit to those who are suffering from congestive heart failure and proteinuria or renal insufficiency.